INTRODUCTION
Dysfunctional uterine bleeding (DUB) is abnormal genital tract bleeding based in the uterus and found in the absence of demonstrable structural or organic pathology [1,2].

Such bleeding is often the result of endocrinological dysfunction and is associated with the absence of ovulation in 80–85% of cases [3,4]. DUB is a common debilitating problem among women in all age groups and accounts for 20% of gynecology clinic visits [5]. Even though a number of treatment modalities are available, a reliable drug for the management of DUB should meet the requirements such as drug should be effective, convenient to take, cost of the drug must be low, with minimal side effects, and the drug should have longest safety margin. The latest of the pharmacological agents that have become available for the treatment of DUB are selective estrogen receptor modulators. These are designer drugs which have an affinity to the estrogen receptor and act like estrogens in some tissues and have antiestrogenic effects in others [6]. Ormeloxifene is a non-steroidal selective estrogen receptor modulator with strong antiestrogen and weak estrogenic and anti-progestin properties [7]. Ormeloxifene not only preferred as oral contraceptive but also useful for the management of DUB and advanced breast cancer [8-10].

METHODS
This was an interventional study of 99 patients, carried out in gynecological outpatient department of medical college and hospital at Dhule district. It was a 1 year study and comprised of semi-structured pro forma including information related to the physical status of participants. Patients' weight was noted, and menstrual history was taken in detail. Patients who were between 20 and 40 years of age, who are not desirous of pregnancy, and who were with no organic disease were included. A total of 106 patients registered in the OPD of the gynecology department were the study population.

Emphasis was paid on the type of bleeding, duration of bleeding, type of blood loss, duration of cycles, passage of clots, and effect on hemoglobin concentration. Treatment taken for present complaints was enquired and previous menstrual history was also noted. History suggestive of bleeding disorders, diabetes, and thyroid dysfunction was also taken. Obstetric and family history was noted.

Of these patients, 99 patients who were fulfilling inclusion criteria’s and who were ready to participate in the study voluntarily were enrolled. Voluntarily participated patients were given tablet ormeloxifene at the dose of 30 mg biweekly for 2 months. The patient was reassessed after the first 2 months. Blood loss was assessed in a subjective manner and by hemoglobin estimation. In case of a therapeutic response as informed by the patient, the dose was reduced to 30 mg weekly for a further period of 4 months. All patients were treated for 6 months.

Emphasis was paid on the type of bleeding, duration of bleeding, type of blood loss, duration of cycles, passage of clots, and effect on hemoglobin concentration. Treatment taken for present complaints was enquired and previous menstrual history was also noted. History suggestive of bleeding disorders, diabetes, and thyroid dysfunction was also taken. Obstetric and family history was noted.

Of these patients, 99 patients who were fulfilling inclusion criteria’s and who were ready to participate in the study voluntarily were enrolled. Voluntarily participated patients were given tablet ormeloxifene at the dose of 30 mg biweekly for 2 months. The patient was reassessed after the first 2 months. Blood loss was assessed in a subjective manner and by hemoglobin estimation. In case of a therapeutic response as informed by the patient, the dose was reduced to 30 mg weekly for a further period of 4 months. All patients were treated for 6 months. Patients were analyzed after 6 months, and data collected were tabulated and analyzed using computer technology by the SPSS package of statistics. Protocol was submitted to the Institutional Ethics Committee, and the study was started after approval.

RESULTS AND OBSERVATIONS
Of 99 patients, nearly 50.51% of women were in 36–40 years of age group. Maximum number of women, i.e., 52.53% were of third parity. Menorrhagia was the main type of bleeding (58.2%) (Table 1).

In age-wise distribution, 53.40% of women who were having menorrhagia were in 36–40 years of age group (Table 2). Duration of bleeding was 4–5 days in 12.1%, but after ormeloxifene, it changed to 76.8% (p=0.001) (Table 3).
### Table 1: Age, parity, and bleeding pattern-wise distribution of patients

| S. No | Parameter              | Number of patients (%) |
|-------|------------------------|------------------------|
| 1     | Age (Years)            |                        |
|       | 20–25                  | 9 (9.1)                |
|       | 26–30                  | 14 (14.1)              |
|       | 31–35                  | 26 (26.3)              |
|       | 36–40                  | 50 (50.5)              |
| 2     | Parity                 |                        |
|       | 0                      | 4 (4.04)               |
|       | 1                      | 9 (9.09)               |
|       | 2                      | 17 (17.17)             |
|       | 3                      | 52 (52.52)             |
|       | 4                      | 17 (17.17)             |
| 3     | Type of bleeding       |                        |
|       | Menorrhagia            | 58 (58.2)              |
|       | Metropathia hemorrhagia| 10 (10)                |
|       | Polymenorrhagia        | 23 (2.4)               |
|       | Metrorrhagia           | 8 (7.8)                |

### Table 2: Age group wise distribution of type of bleeding

| Parameters               | Age in years (%) | Total |
|-------------------------|------------------|-------|
|                         | 20–25 | 26–30 | 31–35 | 36–40 |       |
| Menorrhagia             | 5 (8.6)| 8 (13.8)| 14 (24.1)| 31 (53.4)| 58 (100)|
| Polymenorrhagia         | 4 (17.4)| 2 (8.7)| 7 (30.4)| 10 (43.5)| 23 (100)|
| Metropathia hemorrhagia | 0 (0)  | 2 (20)| 3 (30)| 5 (50)| 10 (100)|
| Metrorrhagia            | 0 (0)  | 2 (25)| 2 (25)| 4 (50)| 8 (100)|
| Total                   | 9 (9.1)| 1 (14.1)| 26 (26.3)| 50 (50.5)| 99 (100)|

### Table 3: Effect of ormeloxifene treatment for 6 months on the duration of menstrual bleeding

| Duration of bleeding | Pre-intervention n (%) | After intervention n (%) | p value |
|----------------------|------------------------|--------------------------|---------|
| <4 days              | 0 (0)                  | 21 (21.2)                | 0.001   |
| 4–5 days             | 12 (12.1)              | 76 (76.8)                | 0.001   |
| 6–7 days             | 42 (42.4)              | 0 (0)                    | 0.001   |
| ≥8 days              | 45 (45.5)              | 2 (2)                    | 0.001   |

After intervention for 6 months, the frequency of menstrual cycle which was irregular in 74.7% changed to regular (12.1%), and regular cycle pattern (25.3%) increased to 87.9% (Table 4).

Amount of bleeding returns to normal in 68.7% and heavy blood loss turned to 0% from 85.9% (Table 5).

Women showing the history of passage of clots were significantly decreased from 78.9% to 7.07%.

At the time of participation in the study, it was observed that all women were having hemoglobin below 12 g/dl. The cumulative percentage of 70.7% of women was having hemoglobin <10 g/dl, of which 32.3% of women had hemoglobin concentration between 9 and 10 g/dl. After the intervention, the cumulative percentage of women having hemoglobin <10 g/dl reduced to 61.6%, of which most of them, i.e., 36.4% were having hemoglobin (Hb) from 9 to 1 g/dl. Furthermore, there was a significant improvement in Hb concentration in women having Hb in between 10 and 12 g/dl from 29.3% to 38.4% after intervention. Mean Hb concentration of study participants increased from 9.5 g/dl to 10 g/dl at the end of the study.

### DISCUSSION

Wide varieties of treatment modalities are available for treating DUB, from medical therapy to minimally invasive surgery in the form of transcervical resection of the endometrium, thermal ablation, and others to conventional hysterectomy. However, medical treatment should be the preferred modality of treatment when possible [11]. A medical management is the first line of therapy for dysfunctional uterine bleeding. The agents that have been used to treat menorrhagia include iron, cyclooxygenase inhibitors, desmopressin, antifibrinolytics, gonadotropin-releasing hormone agonists, androgens, combined oral contraceptives, and progestins [12]. Ormeloxifene has been found to be safer and effective alternative in the treatment of DUB.

The most common age presentation in our study was between 31 and 40 years. It was believed earlier that DUB is more common in extremes of reproductive ages, but the current scenario does not show strictness in above fact [2]. Study by Agarwal and Singh selected age range of 20–50 years [13]. In clinical practice, age can vary from 30 to 45 years. DUB was seen commonly in multiparous than nullipara or primipara women. Annigeri et al. and Mandal et al. found that 85.33% of multiparous women were having DUB [2,11]. In some studies like Grover et al., only multiparous women were selected as participants [14].

Among bleeding pattern, menorrhagia was the most common (58.2%). In a study conducted by Annigeri et al. and Komaram et al., the common pattern was menorrhagia and was found in 73.16% and 44% of women, respectively [2,15].

45.5% of women were having ≥8 days of bleeding before intervention which reduced to 2% after intervention. Ormeloxifene has a significant effect on bleeding duration. The same results were seen with Shahab et al., Godha et al. [12,16] (mean duration of bleeding reduced to 4.8 g/dl from 9), Grover et al. [14] (total bleeding days decreased by 76% with treatment), Soniya et al. [17] (81.63% of patients got relief from bleeding).
menorrhagia), and Mandal et al. [11] (reduction in menstrual blood flow in 61.11%). Reduction in total bleeding days was indirectly reflected as an increase in Hb level.

The regular menstrual pattern was achieved in 87.9% of women. In a study conducted by Grover et al., 66.7% of women achieved regular menses at the end of 3 months’ treatment [14]. This number may go up after 6 months of treatment.

In our study, 85.9% of women were having heavy bleeding which reduced to zero at the end of treatment. This finding is in line with a study by Singh et al., in which 53.3% pretreatment value reduced to 4.65% [18].

Passages of clots were significantly reduced to 7.07% from 78.9%. There are many studies which show the result in line with our study. There was a significant improvement in Hb concentration. Mean Hb improved from 9.5 to 10 g/dl. There are several studies which showed near similar results (Table 6).

CONCLUSION

Ormeloxifene is an effective alternative and appears to be a promising option for the medical management of DUB. It has a convenient dosing schedule. Ormeloxifene reduced the duration of bleeding significantly, and menstrual cycle became regular. It showed a positive impact on the amount of bleeding. Passages of clots were reduced and mean hemoglobin was increased. Along with being effective, the drug has a good patient acceptability and compliance and simple dosage schedule.

ACKNOWLEDGMENT

Authors are grateful to the Department of Obstetrics and Gynaecology, ACPM Medical College Dhule, and the Department of Pharmacology, Smt. Kashibai Navale Medical College, Pune, for their valuable contribution.

AUTHORS’ CONTRIBUTIONS

Dr. Umesh Sawarkar and Dr. Sarang Deshmukh have contributed in the initiation of concept, design this study, literature search, data acquisition, and data analysis. Dr. Ashwini Raut and Dr. Uma Bhosale have contributed in statistical analysis and manuscript preparation. Dr. Ashok Shenoy has done manuscript editing and review.

CONFLICTS OF INTEREST

There is no conflict of interest.

REFERENCES

1. Bellad GC, Lakshmi KS. Ormeloxifene in the management of dub. J Evid Based Med Healthcare 2015;2:6125-31.
2. Annigeri C, Katti T, Karaddi S. Histopathological spectrum of endometrium in dysfunctional uterine bleeding with respect to age, parity and bleeding pattern. BMR Med 2014;1:1-12.
3. Butler WJ. Normal and abnormal uterine bleeding. In: Rock AJ, Jones HW, editors. TeLinde’s Operative Gynaecology. 9th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2003. p. 461.
4. Chen BH, Guidice LC. Dysfunctional uterine bleeding. West J Med 1998;169:280-4.
5. Aswad JT, Toth TL, Schiff I. Abnormal uterine bleeding in the perimenopause. Int J Fertil 1993;38:261.
6. Goldstein SR, Nanavati N. Selective oestrogen receptor modulator levormeloxifene in the treatment of osteoporosis. Am J Obstet Gynaecol 2002;187:521.
7. Yadav VK. Centchroman: A better alternative for hormonal oral Contraceptive pills. Int J Pharm BioSci 2011;2:587-92.
8. Lai J. Clinical pharmacokinetics and interaction of centchroman - A mini review. Contraception 2010;81:275-80.
9. Zaidi D, Singh N, Ahmed LZ, Sharma R, Balapure A. Ant proliferative effects of curcumin plus centchroman in MCF-7 and MDA MB-231 cells. Int J Pharm Pharm Sci 2011;3:2212-16.
10. Hebbar S. Epilepsy and oral hormonal contraception-Indian perspective. Int J Pharm Pharm Sci 2017;9:1-6.
11. Mandal D, Parmanik S, Surana S, Hazra A, Mandal S, Maity TK. Comparative study of low-dose oral contraceptive pill and ormeloxifene in the treatment of dysfunctional uterine bleeding. Int J Health Allied Sci 2014;3:225-31.
12. Shabab F, Jain S, Jain J, Jain U. Ormeloxifene: Boon to perimenopausal dysfunctional uterine bleeding (DUB) women in avoiding hysterectomies. Int J Med Sci Educ 2014;1:21-9.
13. Agarwal N, Singh S. The efficacy and safety of ormeloxifene in dysfunctional uterine bleeding. J Pharm Biol Sci 2015;5:18-21.
14. Grover S, Chhabra A, Bindu S. a study of ormeloxifene in case of dysfunctional uterine bleeding. Int J Med and Dent Sci 2013;2:162-9.
15. Komaram R, Palla J, Chintada GS. A study of efficacy of ormeloxifene in the pharmacological management of dysfunctional uterine bleeding. J Clin Diaq Res 2013;7:2534-6.
16. Godha Z, MObstein Z, Haktim S, Waseem S. Comparative study of ormeloxifene and medroxyprogesterone acetate in abnormal uterine bleeding. J Obstet Gynecol India 2016;66:S395-9.
17. Soniya P, Verma A, Verma P, Gupta R, Sharma B. Role of ormeloxifene in management of abnormal uterine bleeding. Sch J App Med Sci 2017;5:796-9.
18. Singh HO, Singh A, Dhole TN, Nain S. Effect of ormeloxifene for management of dysfunctional uterine bleeding. Biochem Physiol 2015;4:174.
19. Bhattacharyya TK, Banerji A. Efficacy of selective estrogen receptor modulator: Ormeloxifene in management of dysfunctional uterine bleeding. J Obstet Gynecol 2002;187:521.
20. Jacob KJ, Mini, Deepak AV. A comparative study on the effectiveness of ormeloxifene versus norethisterone in the management of perimenopausal dysfunctional uterine bleeding. IAIM 2015;2:87-92.
21. Ahmed SB, Mogri S, Barala S. Role of ormeloxifene in the management of dysfunctional uterine bleeding. A prospective study. Int J Reprod Contracept Obstet Gynecol 2016;5:4373-6.
22. Dhananjay BS, Nanda SK. Role of sevista in the management of dysfunctional uterine bleeding. J Clin Diaq Res 2013;7:132-4.
23. Khan SA, Manzoor M, Abdullah A, Banoo A. Efficacy and safety of ormeloxifene in the management of dysfunctional uterine bleeding. J Dent Med Sci 2014;13:39-42.